Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer

  • End date
    Nov 1, 2023
  • participants needed
  • sponsor
    Fox Chase Cancer Center
Updated on 8 March 2022
total bilirubin
absolute neutrophil count
lung cancer
definitive treatment
neutrophil count
esophageal cancer
concurrent chemotherapy
esophagus cancer
lung carcinoma


Phase I study with the hypothesis that Pulsed Low Dose Radiation (PLDR) radiation delivery technique can significantly decrease the rate of severe acute esophagitis in patients receiving concurrent Chemo-radiation therapy (CRT) for non-small cell lung cancer or esophageal cancer while maintaining similar efficacy. For these patients, the rate of severe acute esophagitis during concurrent CRT is high (approximately 20%) when conventional external beam radiation is utilized. Severe acute esophagitis can cause many adverse consequences such as severe discomfort, weight loss, hospitalization, interruption/early termination of treatment, and worse surgical complications for those who receive surgery after CRT. PLDR radiation has the potential to maintain the tumor control rates of conventional radiation while decreasing the toxicity to the surrounding normal tissue 29-35.

We have completed accrual to a phase I PLDR radiation study, in which patient received palliative re-irradiation with PLDR technique for their metastatic disease in previous irradiated field. In that phase I study, PLDR demonstrated safety for acute toxicities in the setting of re-irradiation for a total dose of 50 Gy, with analysis of 60 Gy pending. The follow up time for that phase I study is limited as most enrolled patients have short overall survival due to their terminal illness.

This proposed phase I study is, to our knowledge, the first clinical study with combination of PLDR radiation and concurrent chemotherapy for definitive treatment.

Condition Lung Cancer, Esophageal Cancer
Treatment carboplatin, Paclitaxel, Pulsed Low Dose Radiation
Clinical Study IdentifierNCT03094884
SponsorFox Chase Cancer Center
Last Modified on8 March 2022


Yes No Not Sure

Inclusion Criteria

Patient must have pathologically-confirmed and previously untreated
Non-small cell lung cancer, Stage IIIA (T1-3 N2 M0); OR
Localized esophageal cancer, ≥T2, or N+, and M0 according to the American Joint Committee on Cancer (AJCC) 7th edition staging
The planned treatment regimen must be concurrent chemoradiation with
Age > 18 years
Carboplatin-Paclitaxel followed by surgery
Eastern Cooperative Oncology Group (ECOG) performance status is 0-1
Laboratory studies must meet each of the following criteria (with labs drawn within 4 weeks prior to the registration)
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
Platelets ≥100,000 cells/mm3
Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable)
Creatinine ≤2 X the upper limit of normal
Bilirubin ≤ 1.5 X upper limit of normal
Aspartate transaminase (AST) ≤ 3 X upper limit of normal
Men and women of childbearing potential must be willing to exercise an effective form
Patients must be able to read and write English to comply with the questionnaire portions of the protocol
of birth control (abstinence/contraception) while on study and for 3 months
Subjects must sign a written informed study consent and HIPAA consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up
after therapy completed

Exclusion Criteria

Patients who have had previous radiotherapy in the thorax
Patients who have a history of ataxia telangiectasia or other documented history of radiation hypersensitivity
Patients who have a history scleroderma or other active connective tissue disease
Women of childbearing potential must not be pregnant with a negative urine pregnancy test within 72 hours prior to registration and non-lactating; postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential; woman status post oophorectomy or hysterectomy are considered non-childbearing potential
Patients who have uncontrolled inter-current illness including, but not limited to, psychiatric illness/social situations that would limit compliance with study requirements
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note